Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?

Charlotte Rigaud, Rachid Abbas, David Grand, Véronique Minard-Colin, Nathalie Aladjidi, Nimrod Buchbinder, Nathalie Garnier, Geneviève Plat, Marie Laure Couec, Mylène Duplan, Anne Lambilliotte, Claudine Schmitt, Thierry Leblanc, Laurence Lamant, Laurence Brugières

    Research output: Contribution to journalArticlepeer-review

    8 Citations (Scopus)

    Abstract

    In anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALK+ ALCL), positive minimal residual disease (MRD+) after the first chemotherapy course was proven of strong prognostic significance. We aimed to validate these results in 138 French patients. Eighty-seven patients had a detectable minimal disseminated disease at diagnosis (MDD+). Early MRD assessment was performed in 33 of 87 patients and was positive in 18 and negative in 15 (MRD−). Three-year progression-free survival was significantly correlated with the MDD/MRD status: 81.1% in MDD−, 69.6% in MDD+/MRD−, and 15.2% in MDD+/MRD+ patients. In conclusion, we confirmed on an independent cohort that the MDD/MRD status has strong prognosis significance in ALK+ ALCL.

    Original languageEnglish
    Article numbere28982
    JournalPediatric Blood and Cancer
    Volume68
    Issue number6
    DOIs
    Publication statusPublished - 1 Jun 2021

    Keywords

    • ALCL
    • MRD
    • anaplastic large cell lymphoma
    • minimal residual disease

    Cite this